Eli Lilly's retatrutide, a triple-receptor weight loss drug targeting GLP-1, GIP, and glucagon, showed significant effectiveness in Phase 3 trials, with patients on the lowest 4-mg dose losing an average of 12.7% of body weight over 80 weeks. The drug also substantially reduced blood sugar levels and improved heart health markers, though gastrointestinal side effects and rare neurological symptoms were observed.
Eli Lilly's experimental GLP-1 medication retatrutide produced average weight loss of 49.6 pounds in people with Type 2 diabetes at the highest dose over 80 weeks, with those having higher BMI losing even more. The company plans to seek FDA approval as a biologic drug before March 2027, a classification that would provide longer market exclusivity than alternative categories.
Eli Lilly reported that its combination treatment eloraTZP, combining an amylin receptor agonist with Zepbound, achieved 23.3% average weight loss in patients with obesity/overweight and type 2 diabetes, outperforming its triple-G candidate retatrutide in this population. At the highest dose, patients lost an average of 54.1 pounds over 48 weeks with improved blood sugar control, though gastrointestinal adverse events led to discontinuation in up to 27% of patients. Lilly plans to initiate phase 3 trials in late 2026.
Eli Lilly presented detailed phase 3 data for retatrutide, a triple-G obesity drug, showing 34.9% of patients on the highest dose lost at least 25% of body weight compared to 4% on placebo. The company plans to file for FDA approval in Q1 2025, positioning retatrutide to compete with its existing tirzepatide while demonstrating superior weight loss but more modest blood sugar effects.
Eli Lilly's experimental GLP-1 drug retatrutide produced record weight loss of up to 60 pounds (23% of body weight) in people with Type 2 diabetes in late-stage trials, surpassing results from competing drugs semaglutide and tirzepatide. The triple agonist also lowered blood sugar levels and helped with sleep apnea and arthritis pain, with the company planning FDA approval filing in early 2025.